RC
CYT

RBF Capital’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

RBF Capital’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-117,295
Closed -$357K – 581
2023
Q4 		$357K Hold
117,295
– – 0.02% 434
2023
Q3 		$333K Hold
117,295
– – 0.02% 412
2023
Q2 		$305K Hold
117,295
– – 0.02% 424
2023
Q1 		$213K Sell
117,295
-33,987
-22% -$55.2K 0.02% 444
2022
Q4 		$250K Sell
151,282
-1,100
-0.7% -$1.76K 0.02% 428
2022
Q3 		$293K Hold
152,382
– – 0.02% 412
2022
Q2 		$456K Buy
+152,382
New +$389K 0.03% 355

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

RBF Capital's CYT Position: Q1 2024 in Review

RBF Capital sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 117,295 shares — an estimated $357K sold.

RBF Capital first reported a position in CYT in Q2 2022 and held it in 7 quarters. The position peaked at $456K in Q2 2022. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • RBF Capital reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • RBF Capital sold 117,295 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $357K.
  • RBF Capital first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
  • RBF Capital's Cyteir Therapeutics, Inc. Common Stock position peaked at $456K in Q2 2022.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on RBF Capital's 13F filing for Q1 2024, filed 15 May 2024.